



A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions by Industry




May 2016 Deal highlights:

- **Kineta** \$7.2M (Award)
 - **Aqueduct Critical Care** \$3.1 (Equity)
 - **Spiral Genetics** \$50,000 (Unknown)
 - **Cytodyn** \$4.3M (Equity)
 - **Mental Health Data Services** \$333,333 (Equity)
 - **Ave Maria Biotechnology** \$50,000 (Equity)
 - **PhaseRx** \$18.5M (IPO)
 - **Haverhill Genetics** \$125,000 (Debt)
 - **Vicis** \$6M (Equity)
 - **Litesprite** \$50,000 (Debt)
- May total:** \$40,437,788
2016 running total (Jan-May 30th): \$2,111,018,287

Life Science Transactions by Quarter: 2013 - 2015

At the end of Q1 2016, life science transactions totaled nearly \$2 billion, more than doubling first quarter transactions in 2015, and just \$350 million shy of the \$2.35 billion total in Q2 of 2015.



Highlights from 1st quarter of 2016

- **Physio-Control** acquired by Stryker Corporation for \$1.28 billion.
- **The Paul G. Allen Frontiers Group** launched as the life sciences funding arm of the Allen Institute with \$100 million fund.
- **M3 Biotechnology** raised \$10 million (Equity). **Glycostasis** acquired by Eli Lilly and Company for an undisclosed amount.
- **Cytodyn** raised \$30.5 million (Equity).
- **Vicis** raised an \$8 million seed round.

*As of April 1, 2016

Check out the past issues of the Washington Life Science Report at:

<http://www.lifesciencewa.org/?page=WAINvestment>

Washington-based Life Science Transactions 2016

Date	Company	Type	Amount
01/11/16	Spiral Genetics	Unknown	\$50,000
01/12/16	Blaze Bioscience	Debt	\$991,000
01/14/16	Stemgenics	Equity	\$930,000
01/20/16	Vicis	Seed	\$8,000,000
01/25/16	Clario Medical Imaging	Equity	\$185,000
02/02/16	ID Genomics	Equity	\$50,000
02/02/16	Oricula Therapeutics	Grant	\$2,060,000
02/11/16	M3 Biotechnology	Equity	\$10,000,000
02/11/16	Spiral Genetics	Unknown	\$50,000
02/16/16	KPI Therapeutics	Debt	\$50,500
02/16/16	Physio-Control	Acquisition	\$1,280,000,000
02/17/16	Glycostasis	Acquisition	undisclosed
02/23/16	Cytodyn	Equity	\$30,574,665
02/24/16	Ave Maria Biotechnology	Equity	\$40,000
02/29/16	VitalWare	Series A	undisclosed
03/03/16	LabConnect	Venture Equity	\$4,000,000
03/11/16	Allen Institute for Brain Science	Contract	\$18,700,000
03/16/16	Ave Maria Biotechnology	Equity	\$350,000
03/17/16	Act X	Unknown	\$308,810
03/22/16	Breast Microseed	Debt	\$100,000
03/22/16	Seattle Children's Research Institute	Grant	\$1,000,000
03/23/16	University of Washington	Grant	\$250,000
03/23/16	Frazier Healthcare Partners	Fund	\$525,000,000
03/24/16	The Paul G. Allen Frontiers Group	Fund	\$100,000,000
04/06/16	2Morrow	Debt	\$325,000
04/06/16	Cyrus Biotechnology	Debt	\$535,000
04/07/16	Medstreaming LLC	Equity	\$12,200,000
04/07/16	Prevencio, Inc	Debt	\$675,000
04/08/16	Medstreaming LLC	Equity	\$2,500,000
04/12/16	Silverback Therapeutics	Equity	\$10,000,000
04/14/16	Vicis	Series A	\$4,000,000
04/18/16	Juno Therapeutics	Partnership	\$50,000,000
04/23/16	ID Genomics	Grant	\$3,000,000
04/27/16	Cardiac Insight	Debt	\$2,505,524
04/29/16	Ave Maria Biotechnology	Equity	\$2,200,000
05/05/16	Kineta	Award	\$7,200,000
05/10/16	Aqueduct Critical Care	Equity	\$3,067,177
05/10/16	Spiral Genetics	Unknown	\$50,000
05/11/16	Cytodyn	Equity	\$4,301,500
05/11/16	Mental Health Data Services	Equity	\$333,333
05/13/16	Ave Maria Biotechnology	Equity	\$50,000
05/17/16	PhaseRx	IPO	\$18,500,000
05/20/16	Haverhill Genetics	Debt	\$125,000
05/24/16	Vicis	Equity	\$6,000,000
05/25/16	Kineta Three, LLC	Equity	\$760,778
05/26/16	Litesprite	Debt	\$50,000
2016 Running Total as of May 30, 2016			\$2,111,018,287

Don't see a transaction listed?

Contact Yesenia Green at yesenia@lifesciencewa.org